Analyst Rating Update on Tobira Therapeutics (TBRA)

Tobira Therapeutics (TBRA) : 4 brokerage houses believe that Tobira Therapeutics (TBRA) is a Strong Buy at current levels. Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 4 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.

Tobira Therapeutics (TBRA) : Currently there are 4 street experts covering Tobira Therapeutics (TBRA) stock. The most bullish and bearish price target for the stock is $22 and $11 respectively for the short term. The average price target of all the analysts comes to $17.5. The estimated standard deviation from the target is $4.65.

For the current week, the company shares have a recommendation consensus of Buy.


Tobira Therapeutics (NASDAQ:TBRA): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $4.00 and $3.82 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $4.16. The buying momentum continued till the end and the stock did not give up its gains. It closed at $4.13, notching a gain of 3.25% for the day. The total traded volume was 824,797 . The stock had closed at $4.00 on the previous day.

Tobira Therapeutics, Inc., formerly Regado BioSciences, Inc., is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Companys lead product candidate, cenicriviroc (CVC), is an immunomodulator that can be used to treat a number of diseases, including non-alcoholic steatohepatitis (NASH), kidney fibrosis, HIV-1 and others. The Company is engaged in clinical studies for CVC, including the CENTAUR Study, an international, randomized Phase IIb study of CVC, and placebo in patients with NASH and liver fibrosis (NCT02217475). The Company has initiated ORION, a Phase IIa Study of Cenicriviroc in obese patients with fatty liver disease. It is also engaged in the Phase I pioglitazone safety combination study. NASH is a type of non-alcoholic fatty liver disease, or NAFLD. NAFLD is a liver disease and is associated with obesity and type-2 diabetes.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.